GC376

protease inhibitor

Also Known As:

(beta S)-alpha-hydroxy-beta-(((2S)-4-methyl-1-oxo-2-(((phenylmethoxy)carbonyl)amino)pentyl)amino)-2-oxo-3-pyrrolidinepropanesulfonic acid; (beta S)-alpha-hydroxy-beta-(((2S)-4-methyl-1-oxo-2-(((phenylmethoxy)carbonyl)amino)pentyl)amino)-2-oxo-3-pyrrolidinepropanesulfonic acid (1:1) sodium salt; GC 376; GC-376; GC-376 free acid; sodium (2S)-2-((S)-2-(((benzyloxy)carbonyl)amino)-4-methylpentanamido)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonate

Networked: 19 relevant articles (4 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Chen, Yeh: 2 articles (05/2022 - 01/2020)
2.	Wang, Yu-Chuan: 2 articles (05/2022 - 01/2020)
3.	Arutyunova, Elena: 2 articles (01/2022 - 01/2020)
4.	Chang, Kyeong-Ok: 2 articles (01/2022 - 01/2018)
5.	Fischer, Conrad: 2 articles (01/2022 - 01/2020)
6.	Groutas, William C: 2 articles (01/2022 - 01/2018)
7.	Khan, Muhammad Bashir: 2 articles (01/2022 - 01/2020)
8.	Kim, Yunjeong: 2 articles (01/2022 - 01/2018)
9.	Lamer, Tess: 2 articles (01/2022 - 01/2020)
10.	Lemieux, M Joanne: 2 articles (01/2022 - 01/2020)

Related Diseases

1.	Feline Infectious Peritonitis 01/01/2022 - "An Mpro inhibitor, GC376, has been shown to treat feline infectious peritonitis (FIP), a fatal infection in cats caused by internal mutations in the feline enteric coronavirus (FECV). " 01/01/2018 - "Objectives The safety and efficacy of the 3C-like protease inhibitor GC376 was tested on a cohort of client-owned cats with various forms of feline infectious peritonitis (FIP). " 01/01/2020 - "Here we show that a clinically approved anti-HCV drug, Boceprevir, and a pre-clinical inhibitor against feline infectious peritonitis (corona) virus (FIPV), GC376, both efficaciously inhibit SARS-CoV-2 in Vero cells by targeting Mpro. " 01/01/2021 - "Protease inhibitor GC376 for COVID-19: Lessons learned from feline infectious peritonitis." 01/01/2022 - "Here, we report the development of the enzyme and cell-based assays for the 3CLpro of GI.1c/RHDV, recombinant GI.3P-GI.2 (RHDV2/b), and GII.1/European brown hare syndrome virus (EBHSV) as well as the identification of potent lagovirus 3CLpro inhibitors, including GC376, a protease inhibitor being developed for feline infectious peritonitis. "
2.	Infections 05/18/2022 - "The broad-spectrum anti-coronaviral drug, GC376, was repurposed to target canine coronavirus (CCoV), which causes gastrointestinal infections in dogs. " 11/01/2021 - "The pan-coronavirus Mpro inhibitor, GC376, was utilized in this assay and effective inhibition of intracellular CoV2 Mpro was found to be consistent with levels required to inhibit CoV2 infection of human lung cells. " 01/01/2020 - "Finally, we explored the substrate specificity of PEDV 3CLpro at the P2 site and analyzed the effects of Leu group modification in GC376 on inhibiting PEDV infection. " 01/01/2022 - "An Mpro inhibitor, GC376, has been shown to treat feline infectious peritonitis (FIP), a fatal infection in cats caused by internal mutations in the feline enteric coronavirus (FECV). " 01/27/2021 - "Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model."
3.	COVID-19 12/01/2021 - "Notably, low-dose combined application of GS441524 with GC376 could effectively protect mice against SARS-CoV-2 infection via i.n. " 01/01/2020 - "Due to the conservation of structure and catalytic mechanism of coronavirus main protease, repurposition of GC376 against SARS-CoV-2 may be an effective way for the treatment of COVID-19 in humans. " 01/01/2020 - "Given that sufficient safety and efficacy data are available for GC376 as an investigational veterinary drug, expedited development of GC376, or its optimized analogues, for treatment of SARS-CoV-2 infection in human is recommended." 01/27/2021 - "This study supports the notion that the K18-hACE2 mouse model is suitable to study antiviral therapies against SARS-CoV-2, and GC-376 represents a promising lead candidate for further development to treat SARS-CoV-2 infection." 01/01/2021 - "This study supports the notion that GC-376 represents a promising lead candidate for further development to treat SARS-CoV-2 infection and that the K18-hACE2 mouse model is suitable to study antiviral therapies against SARS-CoV-2."
4.	Neurologic Manifestations (Neurological Manifestations) 01/01/2018 - "GC376 was administered subcutaneously every 12 h at a dose of 15 mg/kg. Cats with neurologic signs were excluded from the study. "
5.	Coronavirus Infections 01/01/2021 - "Since both GC373 and GC376 have already been successfully used in treating animal coronavirus infection, they can be considered as strong drug candidates for COVID-19 in humans. " 04/01/2022 - "Given the structural similarities of the viral enzymes of different coronaviruses (CoVs), we investigated the potency of the anti-SARS-CoV-2 agents boceprevir and GC376 for counteracting seasonal coronavirus infections. " 01/01/2020 - "Feline infectious peritonitis, a fatal coronavirus infection in cats, was successfully treated previously with a prodrug GC376, a dipeptide-based protease inhibitor. "

Related Drugs and Biologics

1.	Protease Inhibitors (Protease Inhibitor)
2.	K-18 conjugate (K18)
3.	GS-441524
4.	Nucleotides
5.	Antiviral Agents (Antivirals)
6.	Peptide Hydrolases (Proteases)
7.	nirmatrelvir
8.	Enzymes
9.	Viral Antigens
10.	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamide

Related Therapies and Procedures

1.	Therapeutics